Comparing of Cox model and parametric models in analysis of effective factors on event time of neuropathy in patients with type 2 diabetes

Sadegh Kargarian-Marvasti, Shahnaz Rimaz¹, Jamileh Abolghasemi², Iraj Heydari^{3,4}

Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, ¹Radiation Biology Research Center, Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, ²Department of Biostatistics, Faculty of Health, Iran University of Medical Sciences, ³Endocrine Research Center, Firouzgar Hospital, Iran University of Medical Sciences, ⁴Department of Endocrinology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Background: Cox proportional hazard model is the most common method for analyzing the effects of several variables on survival time. However, under certain circumstances, parametric models give more precise estimates to analyze survival data than Cox. The purpose of this study was to investigate the comparative performance of Cox and parametric models in a survival analysis of factors affecting the event time of neuropathy in patients with type 2 diabetes. **Materials and Methods:** This study included 371 patients with type 2 diabetes without neuropathy who were registered at Fereydunshahr diabetes clinic. Subjects were followed up for the development of neuropathy between 2006 to March 2016. To investigate the factors influencing the event time of neuropathy between 2006 to March 2016. To investigate the factors influencing the event time of neuropathy, significant variables in univariate model (P < 0.20) were entered into the multivariate Cox and parametric models (P < 0.05). In addition, Akaike information criterion (AIC) and area under ROC curves were used to evaluate the relative goodness of fitted model and the efficiency of each procedure, respectively. Statistical computing was performed using R software version 3.2.3 (UNIX platforms, Windows and MacOS). **Results:** Using Kaplan–Meier, survival time of neuropathy was computed 76.6 \pm 5 months after initial diagnosis of diabetes. After multivariate analysis of Cox and parametric models, ethnicity, high-density lipoprotein and family history of diabetes were identified as predictors of event time of neuropathy (P < 0.05). **Conclusion:** According to AIC, "log-normal" model with the lowest Akaike's was the best-fitted model among Cox and parametric models. According to the results of comparison of survival receiver operating characteristics curves, log-normal model was considered as the most efficient and fitted model.

Key words: Cox proportional hazards model, diabetes, Kaplan-Meier, neuropathy, parametric models

How to cite this article: Kargarian-Marvasti S, Rimaz S, Abolghasemi J, Heydari I. Comparing of cox model and parametric models in analysis of effective factors on event time of neuropathy in patients with type 2 diabetes. J Res Med Sci 2017;22:115.

INTRODUCTION

Diabetic neuropathy (DN) is a common and dangerous complication of diabetes accounting for highest healthcare spending and morbidity in diabetic patients and may cause profound disability in diabetic patients. Major clinical symptoms of DN include numbness, tingling, muscle weakness, loss of sensation, and severe pain that may progress to diabetic foot ulcers and finally lead to limb amputation in diabetic patients.^[1,2]

Access this article online
Quick Response Code:
Website:
www.jmsjournal.net
DOI:
10.4103/jrms.JRMS_6_17

The prevalence of DN varies from one country to another and has been reported within a wide range of 1.5%–100% in patients with type 2 diabetes. This variation can be attributed to various diagnostic methods for DR.^[3] A meta-analysis on 21 studies by Sobhani *et al.* between 1991 and 2013, estimated the prevalence of diabetic peripheral neuropathy as 53% in Iran showing high prevalence of DR in Iran, to the extent which more than half of diabetic patients are affected with one type of DN.^[4] Nevertheless, it can be concluded that one-third of diabetic patients suffer from DR.^[5]

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Address for correspondence: Prof. Shahnaz Rimaz, Radiation Biology Research Center, Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, Tehran, Iran. E-mail: srimaz2000@yahoo.com Received: 16-01-2017; Revised: 28-05-2017; Accepted: 18-07-2017

Many studies have focused on contributing factors associated with neuropathy in diabetic patients. Accordingly, the most significant variables for the event of neuropathy included gender, age, family history of diabetes, type of treatment, cholesterol level, duration of diabetes, high-density lipoprotein (HDL), low-density lipoprotein (LDL), glycated hemoglobin (HbA1c) level, habitat (rural or urban), smoking, creatinine, blood urea nitrogen (BUN), fasting blood sugar (FBS), hypertension (systolic and diastolic), height, weight, triglycerides, and body mass index (BMI).

Survival analysis was applied to study for occurrence of event and the time of occurrence of an event.^[6] Unlike linear and logistic regression, in survival analysis, if censoring occurs through the follow-up, all data available on each participant will be used over the entire presence of participant during the study.^[7] There are two types of regression models for survival data; (1) Cox proportional hazard model as a semi-parametric model; and (2) parametric models such as Weibull, exponential, log-logistic, and log-normal models. Cox model as a common method for survival modeling has been shown in some settings to be more widespread in use despite its limitations.^[8] However, under certain circumstances, parametric models estimate the parameter more efficient than Cox.^[9]

A number of studies have been conducted to compare various survival regression methods, of which some proposed parametric models as the most appropriate modeling method^[10-18] and some implied to semi-parametric methods such as Cox regression.^[19-21]

Rajaeefard et al. used both parametric and nonparametric methods in a survival analysis of patients with gastric cancer. As such, the results of Cox regression and parametric models were almost consistent.[11]In addition, Ghadimi et al. applied log-logistic model as the best-fitted model in a survival analysis of patients with gastrointestinal cancer.^[18] Furthermore, Weibull model was selected as the best-fitted model in Grover and Sabharwal study that estimated survival time of diabetic nephropathy,^[14] and Roshany et al. study analyzing the survival of patients with acute myocardial infarction.^[15] In addition, log-normal model showed an excellent fit to the data in Askarishahi et al. study analyzing factors affecting the event time of retinopathy^[16] and Baghestani et al.^[17] and Orbe et al.^[12] In addition, regression model was shown to be the best-fitted model in studies by Laclé and Valero-Juan determining the risk factors associated with lower-limb amputation due to neuropathy^[20] as well as the study of risk factors for diabetic nephropathy by Viswanathan et al.[21]

This study was aimed to analyze contributing factors in event time of neuropathy in patients with type 2 diabetes,

using Cox and parametric models including exponential, Weibull, log-normal, and log-logistic.

MATERIALS AND METHODS

This cohort study recruited 371 patients with type 2 diabetes (diabetic patients without neuropathy from all 440 diabetic patients) referring to Fereydunshahr diabetes clinic in Fereydunshahr, Iran, by census method. They were continuously followed for the development of DR until the end of 2016. For the diagnosis of diabetes (type 2), fasting blood sugar test was used.^[22] First, patients were investigated by an expert physician using The Michigan Neuropathy Screening Instrument (MNSI). This questionnaire provided information on condition of foot skin, ulceration, Achilles tendon reflex, and vibration sensation. The MNSI examination has 61% sensitive and 79% specific in defining confirmed clinical neuropathy and has a positive predictive value of 56% and a negative predictive value of 83%.^[23] We also performed 10-g monofilament testing on the palm and back of the feet.^[24] Tabatabaei-Malazy et al. proposed simultaneous use of both MHQ questionnaire and monofilament testing to more effectively detect DN in diabetic patients.^[25] The sensitivity and specificity of the 10-g monofilament testing were computed 65%-86% and 58%-71%, respectively.^[26]

Serum total cholesterol and triglycerides, LDL, HDL, HbA1c, and glucose level were measured by standard biochemical kits and glucose oxidase method kit (Pars Azmoon, Tehran, IR Iran). The sensitivity of these kits for measuring of serum total cholesterol, triglycerides, LDL, and HDL were 95%, 99%, 99%, and 99%, respectively.^[27] The precision of these kits for measuring of HbA1c, BUN, creatinine and glucose level was 99%, 99%, 100%, and 99%, respectively. Reference range of these variables are including triglycerides (normal: <200 mg/dl), cholesterol (normal: <200 mg/dl), HbA1c (change of therapy: >8%), urea UV (13–36 g/24 h), creatinine (men: 0.7–1.4 mg/dl and women: 0.6–1.3 mg/dl), and HDL (\geq 35 mg/dl).

Data regarding age, gender, ethnicity, BMI, smoking, family history of diabetes, age at diagnosis, educational level, height, weight, diabetes duration, habitat, occupation, systolic and diastolic hypertension (based on the classification of the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of hypertension; JNC7), type of treatment, blood cholesterol and triglycerides level, Fasting blood sugar (FBS), LDL and HDL levels, BUN, creatinine, and HbA1c levels were extracted from patient's health-care records. Measurement and calibration of the independent variables were done based on "national programme for diabetes prevention and control" and "Iran's package of essential noncommunicable disease interventions for primary health care (IRAPEN). The event (or failure) in this study was diagnosis of neuropathy in diabetic patients. Subjects who were not diagnosed with DN, as well as missing persons (immigrants) at the end of the study, were considered as censored cases (loss to follow-up).

Factors affecting the event time of DN were investigated using univariate and multivariate analysis according to Cox and four parametric models, Weibull, exponential, log-logistic and log-normal to identify the fitted model. Data were analyzed using R software version 3.2.3 (UNIX platforms, Windows and MacOS). After univariate analysis, five variables with statistical significance (P < 0.20) were submitted in a multiple regression model. In addition, data analysis was conducted using regressive-progressive approach (P < 0.05).^[26,28] We also compared survival curves using the Kaplan–Meier method with log-rank test.^[22]

We used Akaike's information criterion (AIC) to evaluate the goodness of fit. In addition, receiver operating characteristics curves (ROC) and area under ROC curves (AUCs) were applied to determine the efficiency of models. ROC curve is the most common measure to estimate sensitivity and specificity in two-state events. However, ROC curves are used to estimate the survival time data in time-dependent events.^[29] The accuracy of the model is measured by the AUC so that an area of one represents a perfect test; an area of 0.5 represents a worthless test.^[30]

RESULTS

A total of 371 diabetic patients without DN entered the study, of whom 114 were male (30.7%) and 257 were female (69.3%). The mean age of the patients was 64 ± 1.15 years (ranged from 31 to 93 years), and the median age was 64.5 years (standard deviation: 11.03 years). Figure 1 shows number and annual trend of diabetic patients and event of neuropathy and Table 1 shows demographic and clinical characteristics of participants with and without DN.

All 371 patients were followed up for 15,544 months (1295 person-year), and the average follow-up for each patient was 41.9 months. According to nonparametric Kaplan–Meier approach, neuropathy was diagnosed 76.6 (5±) months after the initial diagnosis of diabetes (83.8±8 months male vs. 72.7±6 months female). At the end of 10-year follow-up, DN was diagnosed in 31% of the patients (n = 115) and 60.4% (n = 224) were diagnosed without DN (right-censored). In addition, 8.6% of the patients were lost to follow-up (69% of the patients were censored in the study). Cox regression revealed the 1-, 2-, 5- and 8-year survival rates (event-free survival) as 0.867, 0.819, 0.647, and 0.527, respectively.





Results of univariate analysis for all models are shown in Table 2. In all-fitted models, variables including gender, ethnicity, familial history of diabetes, treatment type of diabetes, height, fasting blood sugar, weight, HDL, HbA1c levels, and duration of diabetes were significant. However, systolic blood pressure was significant only in exponential model. These variables were submitted in multiple regression models.

Figure 2 indicates cumulative hazard function of DN in patients with type 2 diabetes, and Table 3 shows the results of multivariate analysis, in Cox regression and parametric models.

According to multivariate analysis, ethnicity in all models, familial history of diabetes in Cox, Weibull, exponential and log-logistic models, and HDL levels in exponential model were identified as contributing factors associated with event time of DN (P < 0.05).

Although univariate analysis results were not different between parametric and semi-parametric models, parametric models showed an excellent fit to the data based on AIC [Table 4]. In addition, "log-normal model" with the lowest values of AIC, provided the excellent fit to the data.

In addition, according to the results of survival ROC, "log-normal model" was recognized as model with the highest efficiency in parametric and semi-parametric models [Figure 3].

DISCUSSION

The main objectives of this study were to (1) investigate contributing factors in the event time of DR in patients with type 2 diabetes using semi-parametric and parametric models; (2) compare the fitness of the models based on AIC; and (3) compare the accuracy and efficiency of models based on the AUC.

Findings of the current study show that ethnicity, HDL level, and family history of diabetes were identified as

Variables Neuropathy (With, n (%) Total (n) P (c) Gender Without, n (%) Without, n (%) 0 Male 25 (21.7) 89 (34.8) 114 0.0 Sender 90 (P3.3) 167 (65.2) 257 77 0.0 Ses 20 (17.4) 57 (22.3) 77 0.0 Ses 20 (22.6) 79 (30.9) 105 Missed 1 (0.9) 15 (5.8) 16 Job 10.9) 15 (5.8) 16 Job 10.9) 15 (5.8) 16 Job 10.2,0 18 (3.1) 11 Endersteeper 42 (2.4) 78 (18.4) 11 Senoking 77 7 29 0.21 Na 104 (90.4) 23 (190.3) 335 35 Senoking 77 7 7 20 21 Na 104 (90.4) 23 (190.3) 35 0.21 Na 104 (90.4) 23 (190.3) 35 0.21	Table 1: Demographic and clinical character	istics of type 2 diabet	ic patients		
With, n (%) Without, n (%) Gender 5 Male 25 (21.7) 89 (34.8) 114 0.0 Famala 90 (78.3) 167 (65.2) 257 0.0 Age -	Variables	Neu	Total (n)	Ρ (χ ²)	
Gender Sector Sector Sector Male 25 (217) 89 (3.4.8) 114 0.0 Age -<		With, <i>n</i> (%)	Without, <i>n</i> (%)		
Male 25 (21,7) 89 (34,8) 114 0.01 Age -<	Gender				
Fenale 90 (78.3) 167 (65.2) 257 Age	Male	25 (21.7)	89 (34.8)	114	0.008
Age	Female	90 (78.3)	167 (65.2)	257	
-55 20 (7.4) 57 (22.3) 77 0.0 55-70 68 (59.1) 105 (41.0) 173 -270 26 (22.6) 79 (30.9) 105 Mused 1 (0.9) 15 (5.8) 16 Houskeeper 82 (71.3) 160 (62.5) 242 0.4 Worker, farmer, stockbreeder, self-employment 17 (14.8) 50 (19.5) 67 0.2 Smoking 3 (2.6) 8 (3.1) 11	Age				
55-70 68 (59.1) 105 (41.0) 173 270 26 (22.6) 79 (30.9) 105 Missed 1 (0.9) 15 (5.8) 16 Job	<55	20 (17.4)	57 (22.3)	77	0.018
s70 26 (22.6) 79 (30.9) 105 Missed 1 (0.9) 15 (5.8) 66 Job 100 100 (92.5) 67 Houskeeper 3 (2.0) 83 (3.1) 11 Employee 3 (2.0) 83 (3.1) 11 Effete, retired, dead 31 (1.3) 38 (4.9) 51 Smoking 7 7 0.2 Yes 11 (9.6) 18 (7.0) 29 0.2 No 0 7 (2.7) 7 0.2 Smoking 0 7 (2.7) 7 0.2 No 36 (7.4) 17 (7.0.4) 257 0.2 Primary education 26 (22.6) 66 (23.0) 82 0 Iliterate 0 13 (5.1) 13 0.2 Primary education 26 (22.6) 66 (23.0) 83 33 0.2 Primary education 32 (2.6) 16 (6.6) 19 0.4 0.4 0.4 0.4 0.4 0.4 0.4 <	55-70	68 (59.1)	105 (41.0)	173	
Missed 1 (0.9) 15 (5.8) 16 Job Identified IdentifiedIdentified <td>≤70</td> <td>26 (22.6)</td> <td>79 (30.9)</td> <td>105</td> <td></td>	≤70	26 (22.6)	79 (30.9)	105	
Job Housekeeper 82 (71.3) 160 (62.5) 242 0.43 Worker, famer, stockbreeder, self-employment 17 (14.8) 50 (19.5) 67 Employee 3 (2.6) 8 (3.1) 11 Effete, retired, dead 13 (11.3) 38 (14.9) 50 Smoking 11 (9.6) 18 (70.3) 335 Missed 0 7 (2.7) 7 Education 11 10 (190.4) 21 (190.3) 335 Missed 0 7 (2.7) 7 20 Primary education 26 (22.6) 56 (23.0) 82 20 Missed 0 13 (5.1) 13 14 Habitat 10 13 (5.1) 13 14 Urban 67 (58.3) 145 (56.6) 212 10 Bachtiari (Lor) 32 (27.8) 503.2) 17 0.02 Fars 18 (61.7) 90 (16.5) 80 30.2) 17 Missed 0 (26.1) 50 (19.5) 80 <	Missed	1 (0.9)	15 (5.8)	16	
Housekeeper B2 (713) (160 (62.5) 624 0.4.4.4 Worker, farmer, stockbreeder, self-employment 17 (14.8) 50 (19.5) 67 Employee 3 (2.6) B (3.1) 11 Effett, retired, dead 13 (11.3) 38 (14.9) 51 Smoking 8 (20.0) 29 0.21 No 004 (190.4) 231 (190.3) 335 Ves 11 (9.6) 18 (7.0) 29 0.21 No 004 (190.4) 231 (190.3) 335 Education 7 (2.7) 7 Primary education 26 (22.6) 56 (23.0) 82 Diploma and higher 3 (2.6) 16 (6.6) 19 Missed 0 13 (5.1) 13 Bislat 7 (56.3) 45 (56.6) 212 Ithiand (Lon) 30 (26.1) 50 (19.5) 80 Educatin 30 (20.1) 50 (19.5)	Job				
Worker, farmer, stockbreeder, self-employment 17 (1.8) 50 (19.5) 67 Employee 3 (2.6) 8 (3.1) 11 Effeter, retired, dead 13 (11.3) 38 (14.9) 51 Smoking 11 (9.6) 18 (7.0) 29 0.21 No 104 (90.4) 231 (90.3) 335 0 Missed 0 7 (2.7) 7 0.21 Missed 0 7 (2.7) 7 0.21 Missed 0 71 (70.4) 257 0.21 Primary education 26 (22.6) 56 (23.0) 62 0 Missed 0 13 (5.1) 13 0.41 Habita 80 (17.7) 101 (39.5) 149 0.44 Urban 67 (58.3) 145 (56.4) 212 0.01 Bakhtair (Lor) 32 (27.8) 65 (33.2) 117 0.02 Tork 30 (26.1) 50 (19.5) 80 0.00 Fars 16 (5.7) 16 (40.6) 178 0.00	Housekeeper	82 (71.3)	160 (62.5)	242	0.435
Employee 3 (2.6) 8 (3.1) 11 Effeter, retired, dead 13 (1.3) 38 (14.9) 51 Smoking	Worker, farmer, stockbreeder, self-employment	17 (14.8)	50 (19.5)	67	
Effete, retired, dead 13 (11.3) 38 (4.9) 51 Smoking	Employee	3 (2.6)	8 (3.1)	11	
Smoking11 (9.6)18 (7.0)290.21Yes11 (9.6)18 (7.0)290.21No04 (90.4)231 (90.3)355Missed07 (2.7)7Education11Illiterate66 (74.8)77 (70.4)2570.21Primary education26 (22.6)56 (23.0)821Diploma and higher3 (2.6)16 (6.6)191Habitat013 (5.1)131Habitat010 (39.5)1490.44Urban67 (58.3)145 (56.6)2121Georgian55 (30.4)102 (39.8)1370.00Bakhtiari (Lor)32 (27.8)85 (33.2)1171Tork30 (26.1)50 (19.5)807Farrs18 (15.7)19 (7.4)371Familah history of diabetes10.9)21 (8.2)22Treatment type of diabetes7164.3)104 (40.6)1780.00Inseed10.9)21 (8.2)2211Treatment type of diabetes7165.9)2810.00Stafo (33 (72.2)144 (56.3)1220.00210Inseed29 (25.2)33 (36.3)1220.00Stafo (33 (72.2)144 (56.3)22711Missed3 (2.6)19 (7.4)2211Stafo (33 (72.2)144 (56.3)22711S	Effete, retired, dead	13 (11.3)	38 (14.9)	51	
Yes11 (9.6)18 (7.0)290.21No104 (90.4)231 (90.3)335Missed07 (2.7)7Education101 (70.4)2570.21plifterate86 (74.8)171 (70.4)2570.21primary education25 (22.6)56 (23.0)822Diploma and higher3 (2.6)16 (6.6)1910Habitat013 (5.1)1313Habitat013 (5.1)1490.44Missed0101 (39.5)1490.44Urban67 (58.3)145 (56.6)21210Edorgian25 (30.4)102 (39.8)1370.02Bakhtari (Lor)22 (27.8)85 (33.2)1170.02Fars18 (15.7)19 (7.4)3710Farsin of diabetes10 (9.0)21 (8.2)2110+ (Yes)74 (64.3)104 (40.6)1780.00- (No)40 (34.8)131 (51.2)17110Missed10 (.9)21 (8.2)2210Farsin type of diabetes16 (5.7)2828Oral84 (73.0)223 (87.1)3070.00- No)18 (15.7)18 (7.0)2622Missed20 (25.2)73 (36.3)1220.00- Staing blood sugar3 (2.6)19 (7.4)220.00- Staing blood sugar3 (2.6)19 (7.4)220.00- Staing blood sugar3 (2.6) <t< td=""><td>Smoking</td><td></td><td></td><td></td><td></td></t<>	Smoking				
No 004 (90.4) 231 (90.3) 335 Missed 0 7 (2.7) 7 Illiterate 66 (74.8) 171 (70.4) 257 0.21 Primary education 26 (22.6) 56 (23.0) 82 0 Diploma and higher 3 (2.6) 16 (6.6) 19 0 Missed 0 13 (5.1) 13 0 Habitat 13 (5.1) 13 (5.1) 13 0 Habitat 0 10 (39.5) 149 0.4' Urban 67 (58.3) 145 (56.6) 212 0 Missed 0 10 (3.9) 10 0 0 Ethnicity 2 (27.8) 85 (33.2) 117 0 0 Fars 18 (5.7) 19 (7.4) 37 0.00 0	Yes	11 (9.6)	18 (7.0)	29	0.284
Missed 0 7 (2.7) 7 Education F 7 7 Education 5 71 (70.4) 257 0.20 Primary education 26 (22.6) 56 (23.0) 82 10 Diploma and higher 3 (2.6) 16 (6.6) 19 10 Missed 0 13 (5.1) 13 14 Habitat 87 (58.3) 145 (56.6) 212 0.44 Urban 67 (58.3) 145 (56.6) 212 0.0 Bakhtair (Lor) 22 (27.8) 85 (33.2) 17 0.00 Tork 30 (26.1) 50 (19.5) 80 0 0.00 Fars 18 (15.7) 19 (7.4) 37 0.00 - (No) 40 (34.8) 131 (51.2) 171 100 10.9 22 17 Familial history of diabetes 74 (64.3) 104 (40.6) 178 0.00 - (No) 10 (39.2) 22 171 100 100 100 100	No	104 (90.4)	231 (90.3)	335	
Education Bill rerate B6 (74.8) 77 (70.4) 257 0.21 Primary education 26 (22.6) 56 (23.0) 82 Diplom and higher 3 (2.6) 16 (6.6) 19 Missed 0 13 (5.1) 13 Habitat Rural 48 (41.7) 101 (39.5) 149 0.44 Urban 67 (58.3) 145 (56.6) 212 44 45	Missed	0	7 (2.7)	7	
Illiterate 86 (74.8) 171 (70.4) 257 0.2i Primay education 26 (22.6) 56 (23.0) 82 100 Diploma and higher 3 (2.6) 16 (6.6) 19 100 Missed 0 13 (5.1) 13 13 Habitat 101 (39.5) 149 0.44 Urban 67 (58.3) 15 (56.6) 212 16 Missed 0 10 (3.9) 10 16 16 Ethnicity 10 10 (3.9) 107 0.00 16 17 0.00 Bakhtiari (Lor) 35 (30.4) 102 (39.8) 137 0.00 16 17 0.00 16 16 17 0.00 16 17 0.00 16 17 0.00 16 17 0.00 16 17 0.00 16 17 0.00 16 17 0.00 16 16 17 0.00 16 16 16 16 16 16 16	Education				
Primary education 26 (22.6) 56 (23.0) 82 Diploma and higher 3 (2.6) 16 (6.6) 19 Missed 0 13 (5.1) 13 Habitat 13 (5.1) 13 Rural 48 (41.7) 101 (39.5) 149 0.4' Urban 67 (58.3) 145 (56.6) 212 117 Bissed 0 10 (3.9) 10 117 Ethnicity 32 (27.8) 85 (33.2) 117 10 Bakhtiari (Lor) 32 (27.8) 85 (33.2) 17 10 Tork 30 (26.1) 50 (19.5) 80 13 Fars 18 (15.7) 19 (7.4) 37 0.00 Familal history of diabetes 1 10.9) 21 (8.2) 22 Treatment type of diabetes 1 10.9) 21 (8.2) 22 Treatment type of diabetes 1 10.9) 21 (8.2) 22 0.00 Fasting blood sugar 3 (1.3) 15 (5.9) 28 <td>Illiterate</td> <td>86 (74.8)</td> <td>171 (70.4)</td> <td>257</td> <td>0.280</td>	Illiterate	86 (74.8)	171 (70.4)	257	0.280
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Primary education	26 (22.6)	56 (23.0)	82	
Missed013 (5.1)13Habitat	Diploma and higher	3 (2.6)	16 (6.6)	19	
HabitatNormalNor	Missed	0	13 (5.1)	13	
Rural 48 (41.7) 101 (39.5) 149 0.44 Urban 67 (58.3) 145 (56.6) 212 Missed 0 10 (3.9) 10 Ethnicity	Habitat				
Urban 67 (58.3) 145 (56.6) 212 Missed 0 10 (3.9) 10 Ethnicity	Rural	48 (41.7)	101 (39.5)	149	0.496
Missed 0 10 (3.9) 10 Ethnicity -	Urban	67 (58.3)	145 (56.6)	212	
Ethnicity Georgian 35 (30.4) 102 (39.8) 137 0.0: Bakhtiari (Lor) 32 (27.8) 85 (33.2) 117 Tork 30 (26.1) 50 (19.5) 80 Fars 18 (15.7) 19 (7.4) 37 Familial history of diabetes - - - + (Yes) 74 (64.3) 104 (40.6) 178 0.00 - (No) 40 (34.8) 131 (51.2) 171 - Missed 10.9 21 (8.2) 22 - Treatment type of diabetes - - - - Oral 13 (11.3) 15 (5.9) 28 - - Both (oral and insulin injected) 18 (15.7) 18 (7.0) 36 - - Issed 29 (25.2) 93 (36.3) 122 0.00 - - Issed 29 (25.2) 144 (56.3) 227 - - - - - - - Variation of diabetes (months) 3 (2.6) 19 (7.4) 32 - - - - -	Missed	0	10 (3.9)	10	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Ethnicity		, , , , , , , , , , , , , , , , , , ,		
Bakhtiari (Lor)32 (27.8)85 (33.2)117Tork30 (26.1)50 (19.5)80Fars18 (15.7)19 (7.4)37Familial history of diabetes74 (64.3)104 (40.6)1780.00- (No)40 (34.8)131 (51.2)171171Missed1 (0.9)21 (8.2)2222Treatment type of diabetes0ral84 (73.0)223 (87.1)3070.00Insulin injected13 (11.3)15 (5.9)2828Both (oral and insulin injected)18 (15.7)18 (7.0)3636Fasting blood sugar29 (25.2)93 (36.3)1220.00<130	Georgian	35 (30.4)	102 (39.8)	137	0.022
Tork30 (26.1)50 (19.5)80Fars18 (15.7)19 (7.4)37Familial history of diabetes $+$ (Yes)74 (64.3)104 (40.6)1780.00- (No)40 (34.8)131 (51.2)171171Missed10.9)21 (8.2)2222Treatment type of diabetes $-$ (No)84 (73.0)223 (87.1)3070.00Insulin injected13 (11.3)15 (5.9)2828Both (oral and insulin injected)18 (15.7)18 (7.0)3636Fasting blood sugar $-$ (13029 (25.2)93 (36.3)1220.00< 130	Bakhtiari (Lor)	32 (27.8)	85 (33.2)	117	
Fars18 (15.7)19 (7.4)37Familial history of diabetes+(Yes)74 (64.3)104 (40.6)1780.00- (No)40 (34.8)131 (51.2)17117118Missed1 (0.9)21 (8.2)2222171Treatment type of diabetes0ral84 (73.0)223 (87.1)3070.00Insulin injected13 (11.3)15 (5.9)2818Both (oral and insulin injected)18 (15.7)18 (7.0)3616Fasting blood sugar29 (25.2)93 (36.3)1220.00<130	Tork	30 (26.1)	50 (19.5)	80	
Familial history of diabetes+ (Yes)74 (64.3)104 (40.6)1780.00- (No)40 (34.8)131 (51.2)171171Missed1 (0.9)21 (8.2)2222Treatment type of diabetes 0 ral84 (73.0)223 (87.1)3070.00Insulin injected13 (11.3)15 (5.9)2828Both (oral and insulin injected)18 (15.7)18 (7.0)3636Fasting blood sugar $29 (25.2)$ 93 (36.3)1220.00< 130	Fars	18 (15.7)	19 (7.4)	37	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Familial history of diabetes		()		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	+ (Yes)	74 (64.3)	104 (40.6)	178	0.0001
Missed1 (0.9)21 (8.2)22Treatment type of diabetes (0.9) $21 (8.2)$ 223 Oral84 (73.0) $223 (87.1)$ 307 0.00 Insulin injected13 (11.3)15 (5.9) 28 Both (oral and insulin injected)18 (15.7)18 (7.0) 36 Fasting blood sugar $(29 (25.2))$ $93 (36.3)$ 122 0.00 ≤13029 (25.2) $93 (36.3)$ 227 0.00 ≤13083 (72.2)144 (56.3) 227 0.00 Seed $3 (2.6)$ 19 (7.4) 22 0.00 $≤130$ $5 (9.1)$ $50 (90.9)$ 55 0.000 $36 < 5 (9.1)$ $50 (90.9)$ 55 0.000 $36 < 722$ $21 (25.6)$ $61 (74.4)$ 82 $72 < 108$ $23 (24.5)$ $71 (75.5)$ 94 $≤108$ $66 (47.1)$ $74 (52.9)$ 140	- (No)	40 (34.8)	131 (51.2)	17 1	
Treatment type of diabetesOral84 (73.0)223 (87.1)3070.01Insulin injected13 (11.3)15 (5.9)28Both (oral and insulin injected)18 (15.7)18 (7.0)36Fasting blood sugar29 (25.2)93 (36.3)1220.01< 130	Missed	1 (0.9)	21 (8.2)	22	
Oral84 (73.0)223 (87.1)3070.01Insulin injected13 (11.3)15 (5.9)28Both (oral and insulin injected)18 (15.7)18 (7.0)36Fasting blood sugar777<130	Treatment type of diabetes				
Insulin injected13 (11.3)15 (5.9)28Both (oral and insulin injected)18 (15.7)18 (7.0)36Fasting blood sugar29 (25.2)93 (36.3)1220.00≤13029 (25.2)93 (36.3)227144 (56.3)227Missed3 (2.6)19 (7.4)220.00Duration of diabetes (months)5 (9.1)50 (90.9)550.00 $36 < 72$ 21 (25.6)61 (74.4)82 $72 < 108$ 23 (24.5)71 (75.5)94≤10866 (47.1)74 (52.9)140BMI 30 30 30	Oral	84 (73.0)	223 (87.1)	307	0.004
Both (oral and insulin injected)18 (15.7)18 (7.0)36Fasting blood sugar29 (25.2)93 (36.3)1220.00≤13083 (72.2)144 (56.3)227Missed3 (2.6)19 (7.4)22Duration of diabetes (months) 55 0.00<36	Insulin injected	13 (11.3)	15 (5.9)	28	
Fasting blood sugar<130	Both (oral and insulin injected)	18 (15.7)	18 (7.0)	36	
<130	Fasting blood sugar				
≤ 130 83 (72.2) 144 (56.3) 227 Missed 3 (2.6) 19 (7.4) 22 Duration of diabetes (months)	<130	29 (25.2)	93 (36.3)	122	0.009
Missed 3 (2.6) 19 (7.4) 22 Duration of diabetes (months)	≤130	83 (72.2)	144 (56.3)	227	
Duration of diabetes (months) 5 (9.1) 50 (90.9) 55 0.00 36~72 21 (25.6) 61 (74.4) 82 72~108 23 (24.5) 71 (75.5) 94 ≤108 66 (47.1) 74 (52.9) 140	Missed	3 (2.6)	19 (7.4)	22	
<36	Duration of diabetes (months)	- ()	., ()		
36<72	<36	5 (9.1)	50 (90.9)	55	0.0001
72<108	36-<72	21 (25.6)	61 (74.4)	82	0.0001
≤108 66 (47.1) 74 (52.9) 140 BMI	72-<108	23 (24.5)	71 (75.5)	94	
BMI	<108	66 (47.1)	74 (52.9)	140	
	BMI	()	(0,)		
<25 21 (18.3) 42 (16.4) 63 0.9	<25	21 (18.3)	42 (16.4)	63	0.915
25-30 49 (42 6) 99 (38 7) 148	25-30	49 (42 6)	99 (38 7)	14.8	0.710
<30 33 (28 7) 74 (28 9) 107	<30	33 (28 7)	74 (28 9)	107	
Missed 12 (10 4) /1 (16 0) 53	Missed	12 (10 /1)	<u>41 (16 0)</u>	53	

BMI = Body mass index

Table 2: Comparison of the final results of fitted Cox and parametric models in univariate analysis for diagnosis of

Variables	Сох	Log-normal	Log-logistic	Weibull	Exponential	
Gender	0.028	0.072	0.048	0.028	0.024	
Age	0.775	0.974	0.874	0.750	0.748	
Job	0.398	0.701	0.551	0.384	0.437	
Smoking	0.504	0.331	0.382	0.471	0.505	
Education	0.256	0.426	0.304	0.263	0.257	
Habitat	0.963	0.645	0.903	0.978	0.950	
Ethnicity	0.012	0.002	0.011	0.015	0.014	
Familial history of diabetes	0.006	0.006	0.008	0.005	0.006	
Treatment type of diabetes	0.128	0.098	0.098	0.078	0.200	
Height	0.085	0.128	0.167	0.099	0.08	
FBS	0.006	0.003	0.004	0.006	0.003	
Weight	0.033	0.022	0.043	0.038	0.029	
BMI	0.449	0.373	0.43	0.490	0.417	
Cholesterol	0.361	0.592	0.442	0.350	0.409	
Triglycerides	0.795	0.607	0.713	0.784	0.842	
HDL	0.024	0.051	0.039	0.028	0.025	
LDL	0.410	0.530	0.446	0.415	0.408	
BUN	0.696	0.749	0.689	0.695	0.629	
Creatinine	0.935	0.814	0.887	0.946	0.716	
HbA1c	0.020	0.009	0.021	0.019	0.016	
Systolic blood pressure	0.221	0.401	0.305	0.280	0.182	
Diastolic blood pressure	0.547	0.661	0.716	0.648	0.513	
Duration of diabetes	0.008	0.001	0.006	0.004	0.033	

BMI = Body mass index; BUN = Blood urea nitrogen; FBS = Fasting blood sugar; HDL = High-density lipoprotein; LDL = Low-density lipoprotein; HbA1c = Glycated hemoglobin

Table 3: Comparison of the final results of Cox and parametric models in multivariate analysis for diagnosis of neuropathy in patients with type 2 diabetes (*P*<0.05)

Variables	Model														
		Cox Weibull		Exponential			Log-logistic			Log-normal					
	HR	Р	95% CI	HR	Ρ	95% CI	HR	Р	95% CI	TR	Р	95% CI	TR	Р	95% CI
Ethnicity	1.83	0.019	1.1-3.0	1.82	0.020	1.1-3.0	1.98	0.014	1.1-3.4	2.21	0.027	1.1-4.5	2.12	0.050	1.1-4.6
Familial history of diabetes	4.58	0.025	1.2-17.3	4.87	0.018	1.3-18.1	4.52	0.028	1.2-17.4	7.47	0.037	1.1-14.9	N	o signifi	cance
HDL	No	o signific	ance	N	o signifi	cance	4.23	0.019	1.3-14.2	Ν	o signifi	cance	Ν	o signifi	cance

HR = Hazard ration; TR = Time ratio; CI = Confidence interval; HDL = High-density lipoprotein



Figure 2: Cumulative hazard function of neuropathy in patients with type 2 diabetes

contributing factors in the event time of DN (P < 0.05). Fars ethnicity was positively associated with DR (P = 0.016). As such, 49% of the Fars diabetic patients reported DN. In addition, the prevalence of DN was reported 38, 27, and 26% in Turkish, Bakhtiari, and Georgian ethnicity, respectively.

Kaplan–Meier survival analysis showed that event time of DN was shorter in Fars ethnicity compared other ethnicities. As such, the Fars ethnicity developed DN about 22 and 15 months earlier than the Georgians and Bakhtiaris ethnicities, respectively. No research has been done on the relationship between ethnicity and DN in Iran. The family history of diabetes was shown as an important risk factor for DN in this study (P = 0.001).

The proportion of DN in patients with a family history of diabetes was higher compared other patients (41% vs.



Figure 3: Accuracy of semi-parametric and parametric models by the area under operating characteristics curve in the prediction of event time of diabetic neuropathy in patients with type 2 diabetes

Table 4: Comparison of fitness of models based on				
Akaike information criterion				
Model	AIC			

Model	AIU
Cox	404
Exponential	327.98
Weibull	326.02
Log-normal	319.32
Log-logistic	322.86
AIC = Akaike information criterion	

23%). The odds of having DN were 2.3 times higher among those with a family history of diabetes compared to patients without a family history of diabetes. In addition, the event time of DN in patients with a family history of diabetes was 16 months shorter than patients without a family history of diabetes, which was supported by other studies.^[31]

According to results of the current study, it can be assumed that genetic factors are likely to play an important role in the development of DN.^[32,33] Several studies focused on the role of genetics (VEGF gene polymorphism) in developing DN.^[32,35] In addition, reduced HDL level was positively associated with DR. HDL is known as "good" cholesterol in that it removes excess cholesterol in the arteries and transport it back to the liver for excretion and elevated HDL levels are associated with lower risk of cardiovascular disease.

According to Pittsburgh^[36] and Tesfay study on the relationship between vascular risk factors and DN (EURODIAB),^[37] reduced HDL levels were significantly associated with DN. Findings of the current study revealed a relationship between HDL level and the event of DN (P = 0.035). In addition, Kaplan–Meier survival analysis showed that the occurrence time of DN was 21.5 months shorter in patients with lower HDL levels than those who have high HDL levels (P = 0.02). In addition, the odds of having DN were higher in patients with lower HDL (41.7% vs. 23%).

Ghorbani-Gholiabad *et al.*,^[6] Orbe *et al.*,^[12] and Pourhoseingholi *et al.*,^[13] evaluated the parametric and semi-parametric models in the survival analysis of patients with gastric cancer. They have argued that parametric regressions had fitted better than Cox. In addition, log-normal model was shown to be the best fitness, which was in accordance with the present study. However, this was not supported by a number of studies (e.g., Teshnizi *et al.*,^[19] and Askarishahi *et al.*^[16]). They proposed Cox model as the best-efficient model. In addition, a number of studies parallel with our study showed that accuracy and fitness of parametric regression were better than Cox regression.

Besides, Weibull model was selected as the best-fitted model in Grover and Sabharwal study that estimated the survival time of DN,^[14] Roshany *et al.* in a study to analyze the survival of patients with acute myocardial infarction,^[15] and Rajaeefard *et al.* in a survival analysis of patients with gastric cancer.^[11] Ghadimi *et al.* in a study on the survival of the patients with gastrointestinal cancer,^[18] log-logistic model had fitted better than Cox regression and other parametric models.

In this study, ROC curves and the AUC criterion were used to compare the accuracy of semi-parametric and parametric models to estimate the survival time of DN. As shown in Figure 2, in parametric models, AUC value is close to one, showing a higher accuracy than semi-parametric Cox regression (which is closer to 0.5). Thus, log-normal model was determined as the most efficient model.

At the end of 10 years follow-up, the cumulative incidence and prevalence of DN in patients with type 2 diabetes in Fereydunshahr was 31% and 41.8%, respectively, which is consistent with other studies in Iran and other parts of the world. The prevalence of DN in patients with type 2 diabetes found in this study was similar to other studies.^[4,37]

The risk of DN (cumulative incidence) in three experimental studies including complications and control of diabetes in Europe with 7 years follow-up,^[37] Pittsburgh study with two follow-ups for 4- and 10-year period,^[36] and San luis effort with 5-year follow-up^[38] was 23.5%, 13%, 34.2%, and 28.6%, respectively. These suggest that the time of follow-up was positively associated with the cumulative incidence of DN.

According to Kaplan–Meier analysis, female diabetic patients developed DN about 11 months earlier than the male patients (83.8 vs. 72.7 months). Moreover, the risk of DN was 13% higher in women than men (P = 0.014). In similar studies, gender has been found as an effective factor in developing DN.^[32]

Limitation

For goodness of fit of parametric models, censoring should not exceed 40%–50%.^[39] The frequency of right-censored data was 69% in this study which may be due to the limited study period.

Although this study was performed with a long-follow-up period (10-year), continuous follow-up is needed to achieve

higher cumulative incidence (higher percentage of DN diagnosis) and reduce the right-censored data.

However, the strengths of this study were as follow as follows: low rate of lost to follow-up (<10%), use of census method for sampling, high sample size (440 patients in start of the study), patients' regular follow-up, and free medical examinations.

CONCLUSION

According to the results of this study, low-levels of HDL were a modifiable risk factor for DN. However, there were also nonmodifiable risk factors including Persian ethnicity and family history of diabetes. Therefore, educational intervention to achieve recommended HDL levels is of a great importance in patients with a family history of diabetes.

Consumption of unsaturated fats (e.g., olive oil, nuts, fish) instead of saturated fats, exercise and increased fiber intake are shown to increase HDL level, as mentioned in many literatures.

Despite the tendency of many researchers to use Cox regression models in survival analysis, parametric models have been shown to provide more precise results than the Cox model, especially, in when fewer right-censored data are presented. In this study, according to AIC and AUC, "log-normal" parametric model, was identified as the best fitted and efficient model in the analysis of the effective factors in the event time of DN.

However, parametric regression models are not selected as the best-fitted models in survival analysis. As a result, various models show different effectiveness in the analysis of different data sets and we need to evaluate the different models to find the most effective model.

Finally, we suggest further research to be done with more follow-up time to increase the rate of DN diagnosis and reduce the right-censored cases as well as using different comparison criteria between various models.

Acknowledgments

This study is part of a thesis approved by Ethics Committee of the Medical University of Iran in January 2016 with the registration code 27445.

Financial support and sponsorship Nil.

Conflicts of interest

The authors have no conflicts of interest.

REFERENCES

- Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR, et al. The prevalence of multiple diabetes-related complications. Diabet Med 2000;17:146-51.
- 2. Wu S, Armstrong DG. Risk assessment of the diabetic foot and wound. Int Wound J 2005;2:17-24.
- 3. Janghorbani M, Rezvanian H, Kachooei A, Ghorbani A, Chitsaz A, Izadi F, *et al.* Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: Prevalence and risk factors. Acta Neurol Scand 2006;114:384-91.
- Sobhani S, Asayesh H, Sharifi F, Djalalinia S, Baradaran HR, Arzaghi SM, et al. Prevalence of diabetic peripheral neuropathy in Iran: A systematic review and meta-analysis. J Diabetes Metab Disord 2014;13:97.
- Zeiqler D. Current evidence for treating diabetic neuropathy. J Peripher Nerv Syst 2000;5:172-5.
- Ghorbani-Gholiabad S, Yazdani-Charati J, Jan-Babaie G. Evaluation of parametric and semi-parametric models in survival analysis of patients with gastric cancer. J Mazandaran Univ Med Sci 2014;24:11-8.
- Kleinbaum D. Survival Analysis a Self-Learning Text. 3rd ed. New York: Springer; 2004.
- 8. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag; 2000.
- 9. Efron B. The efficiency of Cox's likelihood function for censored data. J Am Stat Assoc 1977;72:557-65.
- 10. Giolo SR, Krieger JE, Mansur AJ, Pereira AC. Survival analysis of patients with heart failure: Implications of time-varying regression effects in modeling mortality. PLoS One 2012;7:e37392.
- Rajaeefard A, Dehkordi B, Tabatabaee H, Zeighami B, Safaee A. Applying parametric models for survival analysis of gastric cancer. J Kashan Univ Med Sci (FEYZ) 2009;13:83-8.
- 12. Orbe J, Ferreira E, Núñez-Antón V. Comparing proportional hazards and accelerated failure time models for survival analysis. Stat Med 2002;21:3493-510.
- Pourhoseingholi MA, Hajizadeh E, Moghimi Dehkordi B, Safaee A, Abadi A, Zali MR, *et al.* Comparing cox regression and parametric models for survival of patients with gastric carcinoma. Asian Pac J Cancer Prev 2007;8:412-6.
- 14. Grover G, Sabharwal A. A parametric approach to estimate survival time of diabetic nephropathy with left truncated and right censored data. Int J Probab Stat 2012;1:128-37.
- 15. Roshany D, Azadi NA, Esmail-Nasab N, Yaghoubi M. Application of parametric, semiparametric and nonparametric approaches in survival analysis of patients with acute myocardial. J North Khorasan Univ Med Sci 2011;3: 45-51.
- Askarishahi M, Keshavarzi F, Afkhami-Ardakani M, Falahzadeh H. Using parametric and Cox models in analysis of factors influencing the diagnosis of retinopathy in type II diabetes. Mazandaran Univ Med Sci 2014;24:28-35.
- 17. Baghestani AR, Hajizadeh E, Fatemi R. To evaluate the prognostic factors in using Bayesian interval censoring analysis on survival rate of gastric cancer in Iran. Iran J Epidemiol 2010;3:18-21.
- Ghadimi M, Mahmoodi M, Mohammad K, Zeraati H, Rasouli M, Sheikhfathollahi M, *et al.* Family history of the cancer on the survival of the patients with gastrointestinal cancer in Northern Iran, using frailty models. BMC Gastroenterol 2011;11:104.
- Teshnizi SH, Zare S, Tazhibi M. The evaluation of Cox and Weibull proportional hazards models and their applications to identify factors influencing survival time in acute leukemia. Hormozgan Univ Med Sci 2010;15:269-78.
- 20. Laclé A, Valero-Juan LF. Diabetes-related lower-extremity amputation incidence and risk factors: A prospective seven-year study in Costa Rica. Rev Panam Salud Publica 2012;32:192-8.

- 21. Viswanathan V, Tilak P, Kumpatla S. Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study. Indian J Med Res 2012;136:46-53.
- 22. Ahmadi A, Mobasheri M, Hashemi-Nazari SS, Baradaran A, Choobini ZM. Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study. J Res Med Sci 2014;19:850-4.
- 23. Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, *et al.* Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: Results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med 2012;29:937-44.
- 24. Armstrong DG. The 10-g monofilament: The diagnostic divining rod for the diabetic foot? Diabetes Care 2000;23:887.
- Tabatabaei-Malazy O, Mohajeri-Tehrani M, Madani S, Heshmat R, Larijani B. The prevalence of diabetic peripheral neuropathy and related factors. Iran J Public Health 2011;40:55-62.
- Miranda-Palma B, Sosenko JM, Bowker JH, Mizel MS, Boulton AJ. A comparison of the monofilament with other testing modalities for foot ulcer susceptibility. Diabetes Res Clin Pract 2005;70:8-12.
- 27. Ahmadi A, Hasanzadeh J, Rajaefard A. Metabolic control and care assessment in patients with type 2 diabetes in Chaharmahal & Bakhtiyari Province. Iran J Endocrinol Metab 2009;11:33-9.
- 28. Ahmadi A, Soori H, Sajjadi H. Modeling of in hospital mortality determinants in myocardial infarction patients, with and without type 2 diabetes, undergoing pharmaco-invasive strategy: The first national report using two approaches in Iran. Diabetes Res Clin Pract 2015;108:216-22.
- Klein JP, Moeschberger LM. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2005.
- 30. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105.
- Abolghasemi J, Eshraghian MR, Nasiri Toosi M, Mahmoodi M, Rahimi Foroushani A. Introducing an optimal liver allocation system for liver cirrhosis patients. Hepat Mon 2013;13:e10479.
- Börü UT, Alp R, Sargin H, Koçer A, Sargin M, Lüleci A, *et al.* Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey. Endocr J 2004;51:563-7.
- 33. Hornemann T, Penno A, Richard S, Nicholson G, van Dijk FS, Rotthier A, *et al.* A systematic comparison of all mutations in hereditary sensory neuropathy type I (HSAN I) reveals that the G387A mutation is not disease associated. Neurogenetics 2009;10:135-43.
- 34. Trivedi JR, Phillips L, Chhabra A. Hereditary and acquired polyneuropathy conditions of the peripheral nerves: Clinical considerations and MR neurography imaging. Semin Musculoskelet Radiol 2015;19:130-6.
- Rahimi Z, Moradi M, Nasri H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J Res Med Sci 2014;19:1090-8.
- Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, *et al.* Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study. Diabetes 1989;38:1456-61.
- Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, *et al.* Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-50.
- Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997;20:322-9.
- 39. Nardi A, Schemper M. Comparing cox and parametric models in clinical studies. Stat Med 2003;22:3597-610.